Nucana Stock Price, News & Analysis

NuCana (NASDAQ: NCNA) has announced a significant change in its American Depositary Shares (ADS) ratio, effective August 11, 2025. The ratio will change from 1 ADS representing 25 ordinary shares to 1 ADS representing 5,000 ordinary shares.

This adjustment effectively functions as a 1-for-200 reverse ADS split. The change aims to enhance ADS liquidity and help NuCana regain compliance with Nasdaq's minimum bid price requirement. While shareholders' proportional equity interest remains unchanged, the ADS trading price is expected to increase proportionally.

The transition will be automatic for holders of uncertificated ADSs, while those holding certificated ADSs must surrender them to Citibank for exchange. Fractional ADSs will be sold, with proceeds distributed to affected holders.

NuCana (NASDAQ: NCNA) has successfully canceled all outstanding Series A Warrants that were originally issued during its May 2025 registered direct offering. The company raised the necessary capital through an at-the-market (ATM) offering to complete the cancellation of 59.5 million warrants for a payment of $3.6 million.

This strategic move, announced on June 27, 2025, eliminates all overhanging rights from the May 2025 offering, potentially providing more clarity to the company's capital structure.

NuCana (NASDAQ: NCNA) announced plans to implement a significant change in its American Depositary Shares (ADS) ratio. The company will modify the ratio from 1 ADS representing 25 ordinary shares to 1 ADS representing 5,000 ordinary shares, effective around August 8, 2025.

This change effectively functions as a 1-for-200 reverse ADS split. The move aims to enhance ADS liquidity and help NuCana regain compliance with Nasdaq's minimum bid price requirement. While holders' proportional equity interest remains unchanged, the ADS trading price is expected to increase proportionally, though this is not guaranteed.

NuCana (NASDAQ: NCNA) reported Q1 2025 financial results and provided updates on its cancer drug pipeline. The company's lead program NUC-7738 has shown promising results in treating PD-1 inhibitor-resistant melanoma, leading to an expansion trial with 28 additional patients. NuCana's second program, NUC-3373, is showing positive data in combination with pembrolizumab for advanced solid tumors. The company reported a reduced net loss of £2.5 million in Q1 2025 compared to £6.8 million in Q1 2024. Following a May financing round raising £8.8 million, NuCana's cash position stands at £4.0 million, with runway extended into Q4 2026. Key upcoming milestones include data readouts from both NUC-7738 and NUC-3373 trials, and regulatory guidance from the FDA for NUC-7738's pivotal study in melanoma.

NuCana (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on cancer treatments, has priced a $7 million registered direct offering of 10,845,985 American Depository Shares (ADSs) or pre-funded warrants. Each ADS or warrant is priced at $0.6454 and comes with two additional warrants: a Series A warrant to purchase one ADS at $0.8068 per share and a Series B warrant at $1.61 per share.

The proceeds will fund the company's drug discovery and development programs, along with general corporate purposes including working capital, investments, and potential acquisitions. The offering, managed by Laidlaw & Company as sole placement agent, is expected to close around May 7, 2025.

NuCana (NASDAQ: NCNA) has reported its Q4 and full-year 2024 financial results, highlighting progress in its anti-cancer drug development programs. The company's lead program, NUC-7738, showed promising results in combination with pembrolizumab, achieving disease control in 75% of patients with PD-1 inhibitor-resistant melanoma.

Financial highlights include cash position of £6.7 million as of December 31, 2024, with runway extended into Q3 2025. The company reported a reduced net loss of £19.0 million for 2024, compared to £27.6 million in 2023. Loss per share improved to £0.26 for 2024 from £0.53 in 2023.

Key 2025 milestones include initiating an expansion study of NUC-7738 with pembrolizumab for melanoma patients and seeking FDA guidance on pivotal study design. The company will also continue development of NUC-3373, which has shown positive results in combination studies.

Aurion Biotech has appointed Donald Munoz as Chief Financial Officer, reporting to CEO Greg Kunst. Munoz brings over 30 years of healthcare experience, including nine years as CFO of NuCana plc (NASDAQ: NCNA), where he led a $114 million IPO and $80 million follow-on offering. Previously, he served as CFO at NOXXON Pharma and spent 20 years as a healthcare investment banker at firms including Cowen & Company, Leerink Partners, and Deutsche Bank.

At NuCana, Munoz managed financial operations, investor relations, SEC reporting, audit, tax, and financial planning. Throughout his career, he has completed over 100 financing and strategic advisory transactions. The appointment follows Aurion's announcement of positive six-month top-line data from its CLARA Phase 1/2 clinical trial for AURN001, their lead product candidate targeting corneal endothelial disease.

NuCana reported Q3 2024 financial results and clinical updates. The company presented promising Phase 2 data for NUC-7738 in combination with pembrolizumab, showing disease control in 9 of 12 PD-1 inhibitor-resistant melanoma patients. Phase 1b/2 data for NUC-3373 showed encouraging results in combination with pembrolizumab or docetaxel. Financial highlights include cash position of £11.4 million as of September 30, 2024, with runway expected into Q2 2025. The company reported a reduced net loss of £4.5 million compared to £6.7 million in Q3 2023.

NuCana announced initial data from its Phase 1b/2 study of NUC-3373 in combination therapies. In Module 1, combining NUC-3373 with pembrolizumab showed promising results in 12 advanced solid tumor patients, achieving a 22% objective response rate and 67% disease control rate. Notable cases included a bladder cancer patient achieving 100% target lesion reduction and a melanoma patient showing 81% reduction. In Module 2, NUC-3373 with docetaxel demonstrated extended stable disease in lung cancer patients, with one achieving stability for over 13 months. The combinations were generally well-tolerated, though Module 2 enrollment was paused due to docetaxel-related toxicity concerns.